Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.

Ghent is boosting its biopharma hub with cutting-edge infrastructure, world-class research, and a thriving life sciences ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

The companies Cogent Biosciences, Braveheart Bio, and AAVantgarde bagged the biggest biotech funding rounds overall in ...

Igyxos’ IGX12 brings a fresh approach to infertility treatment, aiming to improve outcomes for both men and women.

Delve into Vandria's technology and its Alzheimer's candidate, VNA-318, the first mitophagy-based candidate in Alzheimer's in ...

The need for change in Novo Nordisk’s operations became irrefutably clear in July, when the company named its new CEO, Maziar Mike Doustdar, and simultaneously issued a profit warning for its ...

In June, AstraZeneca once again turned to the Chinese company CSPC Pharmaceuticals, with whom it initially entered into an exclusive license agreement in October 2024 for an early-stage cardiovascular ...

Since June, the Swiss big pharma company has inked seven major deals. Its shopping spree in September is what has really cemented this trend. One of the biggest deals of last month was its $1.4 ...

The news that the organization led a $35 million funding round for London-based Portal Biotech came about two weeks ago. Portal Biotech’s focus is on the field of proteomics, which is the study of ...

Antibody therapies constitute a vast global market: currently valued at over $250 billion, the market for antibodies is expected to exceed $850 billion worldwide by 2032. Driving forces behind this ...